Navigation Links
Published Data Demonstrates Positron Emission Mammography Has Higher Sensitivity Than PET/CT
Date:10/27/2011

SAN DIEGO, Oct. 27, 2011 /PRNewswire/ -- The Breast journal published new data from a prospective study conducted at the Seoul National University College of Medicine in Korea that shows Positron Emission Mammography (PEM) has a higher sensitivity for tumor detection compared to whole-body PET/CT when using both visual as well as quantitative analysis.  These results were particularly striking and significant for smaller-sized tumors (less than 2 cm), likely due to the improved spatial resolution offered by PEM.  This demonstrates PEM's clinical utility in being able to more effectively diagnosis early stage cancer.

According to recent journal articles, the sensitivity of PET/CT is limited especially for low-grade and small tumors.  Most PET/CT scanners currently provide a spatial resolution at 5 mm or greater; thus limiting PET/CT's ability to depict small-sized tumors such as invasive lobular carcinoma or ductal carcinoma in situ.  This study provides a direct comparison within the same patient population.

A total of 113 breast lesions from 101 patients with a mean tumor size of 2.2 cm, were included in the analysis.  The patients underwent PEM with FDG and whole-body PET/CT before surgical resection. The images were then analyzed visually and quantitatively using the tumor-to-normal tissue uptake ratio (TNR) with a cutoff of 2.5 or greater.  The tumors were classified into 4 groups based on size using pathology measurements prior to detection sensitivity analysis for PEM and PET/CT.  In visual analysis, the overall sensitivity of PEM was 95%, which was significantly higher than the 87% sensitivity found for PET/CT; ( p=0.004).  In addition, the TNR of PEM was significantly higher than that of PET/CT in small tumors (<1 cm; p=0.005 and <2 cm; p<0.001).

PEM is the breast application of the Naviscan high-resolution PET scanner which both can localize as well as characterize the metabolic activity of a lesion.  PEM uses parallel photon detectors in a configuration similar to mammography with breast immobilization, not compression.  It is the only FDA-cleared, CE Certified 3D Molecular Breast Imaging (MBI) device on the market.  The metabolic view assists physicians in making optimal care decisions by providing an ability to distinguish between benign and malignant lesions.

About Naviscan, Inc.

Naviscan, founded in 1995, develops and markets compact, high-resolution PET scanners intended to provide organ-specific molecular imaging and guide radiological and surgical procedures. The Naviscan PET scanner is currently installed and available in breast and imaging centers throughout the U.S. and other parts of the world. The Company is headquartered in San Diego, California and is the first to obtain FDA-clearance and CE Mark for a high-resolution PET scanner designed to image small body parts and for breast biopsy image guidance. For more information, call 1.858.587.3641 or visit www.naviscan.com.

For more information, including images, videos, quotes and links, please visit the social media news release (SMNR) at http://prst.co/BC


'/>"/>
SOURCE Naviscan, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
2. Adlyfe Study on the Detection of Misfolded Proteins Published in the Journal Transfusion
3. Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
4. Results from Study Evaluating PROCRIT(R) in Intensive Care Unit Patients Published in New England Journal of Medicine
5. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
6. Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs
7. New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
8. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
9. Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
10. UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
11. Tumor Eradication Article Published by Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... , Feb. 27, 2017  A ... P. Vallely , MBBS, PhD, FRACS, of  Sydney ... University of Sydney will be published in ... of the American College of Cardiology ... beating heart bypass surgery technique (anOPCABG) reduced ...
(Date:2/27/2017)... Biophysics Corporation, a global medical device manufacturer based in ... growth in 2016 when compared to the previous year based ... fueled by its AffloVest® sales in the United ... global sales of surgical product lines. Said H. ... 25 th year in delivering high-quality, innovative medical devices ...
(Date:2/27/2017)... ROCKVILLE, Md. , Feb. 27, 2017 /PRNewswire/ ... "RegeneRx"), a clinical-stage drug development company focused on ... its licensee for RGN-137, GtreeBNT Co., Ltd., received ... its Phase 3 clinical trial design for RGN-137 ... dermal wound healing gel that incorporates Thymosin beta ...
Breaking Medicine Technology:
(Date:2/27/2017)... ... February 27, 2017 , ... ... overview on laser diffraction analysis as a tool to characterize particle size distributions ... potential to obtain improved results and novel scientific findings. It describes methods of ...
(Date:2/27/2017)... , ... February 27, 2017 , ... POUGHKEEPSIE, N. Y. ... has disclosed that despite scientific studies, the Center for Disease Control ( CDC ) ... disease . Kenneth B. Liegner, M.D. has compiled into a single volume a ...
(Date:2/27/2017)... BC (PRWEB) , ... February 27, 2017 , ... ... drug rehabilitation and alcohol treatment programs in British Columbia, Canada, at https://www.sunshinecoasthealthcentre.ca/ ... to its team. The new hire, Mackenzie Alsager, showcases the Centre's commitment to ...
(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... ... San Francisco and environs, is proud to announce an upgrade to the company's ... the upgraded Yelp page on topics as diverse as Platelet Rich Plasma (PRP) ...
(Date:2/26/2017)... ... February 25, 2017 , ... The February 13, 2017, assassination of Kim ... over nerve agents and the deadly use of chemical weapons. Many questions exist about ... even small doses can be lethal. , Jay Jagannathan, M.D., of Michigan-based Jagannathan Neurosurgical ...
Breaking Medicine News(10 mins):